Genfit (ENXTPA:GNFT) - Stock Price, News & Analysis

GNFT Stock Overview

A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

About the company

GNFT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (12.7x) is below the French market (14.3x)

Earnings are forecast to grow 33.79% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Volatile share price over the past 3 months compared to the French market

Genfit S.A. Competitors

Eurobio Scientific Société anonyme

ENXTPA:ALERS

€258.1m

OSE Immunotherapeutics

ENXTPA:OSE

€196.4m

genOway Société anonyme

ENXTPA:ALGEN

€33.7m

Boiron

ENXTPA:BOI

€568.6m

Price History & Performance

Summary of all time highs, changes and price drops for Genfit
Historical stock prices
Current Share Price	€5.67
52 Week High	€5.80
52 Week Low	€2.84
Beta	1.1
11 Month Change	46.51%
3 Month Change	35.16%
1 Year Change	87.75%
33 Year Change	75.22%
5 Year Change	-57.46%
Change since IPO	-56.25%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GNFT	FR Biotechs	FR Market
7D	13.4%	0.8%	-1.6%
1Y	87.7%	-19.3%	4.6%

Return vs Industry: GNFT exceeded the French Biotechs industry which returned -21.1% over the past year.

Return vs Market: GNFT exceeded the French Market which returned 4.5% over the past year.

Price Volatility

Is GNFT's price volatile compared to industry and market?
GNFT volatility
GNFT Average Weekly Movement	7.4%
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.5%
10% most volatile stocks in FR Market	9.6%
10% least volatile stocks in FR Market	2.3%

Stable Share Price: GNFT's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: GNFT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
1999	169	M. Prigent	www.genfit.com

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

Genfit S.A. Fundamentals Summary

How do Genfit's earnings and revenue compare to its market cap?
GNFT fundamental statistics
Market cap	€282.41m
Earnings (TTM)	€22.27m
Revenue (TTM)	€80.47m

12.7x

P/E Ratio

3.5x

P/S Ratio

Is GNFT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNFT income statement (TTM)
Revenue	€80.47m
Cost of Revenue	€0
Gross Profit	€80.47m
Other Expenses	€58.20m
Earnings	€22.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.45
Gross Margin	100.00%
Net Profit Margin	27.67%
Debt/Equity Ratio	63.9%

How did GNFT perform over the long term?

See historical performance and comparison